In this meeting we are going to refer to all of them as a whole and, particularly to Hemophilia, a hereditary bleeding disorder in which the blood .. Read more does not clot properly, and Acquired Thrombotic Thrombocytopenic Purpura (aTTP), a rare thrombotic microangiopathy , which can be life-threatening and is characterized by hemolytic anemia, severe thrombocytopenia, and tissue ischemia. Today we are going to discuss the nature of drugs for these diseases and high impact drug management models. We are going to show how the lives of these patients have changed. The objectives of this meeting are: to show the unmet needs in these pathologies, to know the state of the art of research on rare hematological diseases and to defend the incentives for MMHH. In this sense, we intend that both the agencies and regulatory entities and funders of these treatments, as well as health professionals, patients and the media participate in the knowledge generated and revealed in this meeting, become aware of the opportunities that arise. offer and make the decision to work for the solution of the problems raised.
- Share your Experience